 This study explored the experiences of patients and caregivers who took part in a randomized controlled trial of regular, low dose, sustained release morphine for chronic breathlessness associated with COPD. The participants reported that receptivity and knowledge about the drug influenced their decision to take it, as did the hope for functional improvement. They also reported that the degree of symptom reduction, improved function, side effect severity and caregiver availability created a net effect that drove their decisions to either continue or discontinue the medication. This article was authored by Jane Phillips, Slavika Kochowska, David Kuro, and others.